EEFSEC deficiency: A selenopathy with early-onset neurodegeneration.
Laugwitz L. et al, (2025), Am J Hum Genet, 112, 168 - 180
Toward target 2035: EUbOPEN - a public-private partnership to enable & unlock biology in the open.
Tredup C. et al, (2024), RSC Med Chem
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease.
Thomas T. et al, (2024), Nat Immunol
A data science roadmap for open science organizations engaged in early-stage drug discovery.
Edfeldt K. et al, (2024), Nat Commun, 15
Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification.
Pouwels KB. et al, (2024), Nat Commun, 15
Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.
Wei J. et al, (2024), Nat Commun, 15
Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.
Pagnamenta AT. et al, (2023), Genome Med, 15
Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.
Bešević J. et al, (2023), J Epidemiol Community Health, 78, 105 - 108
Robustly interrogating machine learning-based scoring functions: what are they learning?
Durant G. et al, (2023)
Integrative GWAS and co-localisation analysis suggests novel genes associated with age-related multimorbidity.
West CE. et al, (2023), Sci Data, 10
Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes.
Thompson KN. et al, (2023), Sci Transl Med, 15
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Wei J. et al, (2023), Nat Commun, 14
Pathogenic Interleukin-10 Receptor Alpha Variants in Humans - Balancing Natural Selection and Clinical Implications.
Aschenbrenner D. et al, (2023), J Clin Immunol, 43, 495 - 511